Insmed 
Welcome,         Profile    Billing    Logout  
 5 Products   6 Diseases  5 Products   12 Trials   456 News 
29 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Arikayce (amikacin liposome inhalation suspension) / Insmed
ARISE, NCT04677543 / 2020-002545-42: Validation of Patient Reported Outcome Measures in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex

Completed
3
99
Europe, US, RoW
ALIS, Amikacin liposome inhalation suspension, ARIKAYCE®, Azithromycin, AZI, Ethambutol, ETH, ELC, Empty liposome control
Insmed Incorporated
Mycobacterium Infections, Nontuberculous
05/23
05/23
ENCORE, NCT04677569 / 2020-003079-16: Study to Evaluate ALIS (Amikacin Liposome Inhalation Suspension) in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex

Active, not recruiting
3
425
Europe, Canada, Japan, US, RoW
ALIS, Amikacin liposome inhalation suspension, ARIKAYCE®, Azithromycin, AZI, Zithromax, Ethambutol, ETH, Myambutol, ELC (matching placebo for ALIS), Empty liposome control
Insmed Incorporated
Mycobacterium Infections, Nontuberculous
11/25
01/26
2005-004389-17: SAFETY AND TOLERABILITY STUDY OF SLIT AMIKACIN 500 MG ONCE DAILY FOR 14 DAYS BY INHALATION IN CYSTIC FIBROSIS STUDY SUBJECTS CHRONICALLY INFECTED WITH PSEUDOMONAS AERUGINOSA

Ongoing
2
10
Europe
SLIT Amikacin, TR02,
Transave, Inc
Cystic Fibrosis with mild to moderate obstructive lung disease and chronic infection with Pseudomonas aeruginosa
 
 
AKAPI, NCT06585020: Amikacin Liposome Inhalation Suspension for Treatment of Mycobacterium Xenopi Pulmonary Infection

Not yet recruiting
2
190
Europe
Arikayce, standard treatment
Centre Hospitalier Universitaire, Amiens, University Hospital, Angers, Hospital Avicenne, University Hospital, Bordeaux, University Hospital, Brest, CH Compiègne, Créteil Hospital, Centre Hospitalier Universitaire Dijon, University Hospital, Grenoble, Centre Hospitalier le Mans, Hôpital de la Croix-Rousse, APHM - Nord, Hôpital Saint Joseph, CH Mulhouse, CH Orléans, Tenon Hospital, Paris, Hôpital Necker-Enfants Malades, CH PERPIGNAN, Poitiers University Hospital, CH Pontoise, CHU de Reims, Rennes University Hospital, CHU de Rouen - Accueil, Central Hospital Saint Quentin, IHU Strasbourg, University Hospital, Tours, CH Abbeville, CH Cannes
Mycobacterium; Xenopi, Lung Diseases
08/26
08/27
NCT06238856: Single Dose Escalation Study of TR02 (Sustained Lipid Inhalation Technology [SLIT™] Amikacin) in Participants With Cystic Fibrosis (CF) Having Chronic Infections of Pseudomonas Aeruginosa

Completed
1
18
NA
SLIT™ Amikacin, TR02, Placebo
Insmed Incorporated
Cystic Fibrosis
02/05
02/05
NCT05999942: A Study to Investigate Lung Deposition of Inhaled Amikacin-loaded Liposomes in Healthy Male Participants

Completed
1
6
NA
Liposomal Amikacin for Inhalation, Amikacin Liposome Inhalation Suspension (ALIS),, Arikayce™
Insmed Incorporated
Healthy Volunteers
06/04
06/04
brensocatib (INS1007) / Insmed
ASPEN, NCT04594369 / 2020-003688-25: A Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib in Participants With Non-Cystic Fibrosis Bronchiectasis

Jan 2024 - Dec 2024: Data from ASPEN trial for non-cystic fibrosis bronchiectasis
Hourglass Apr 2024 - Jun 2024 : Q2'24 - Topline data from ASPEN trial for NCFB
Completed
3
1767
Europe, Canada, Japan, US, RoW
Brensocatib 10 mg, INS1007, Brensocatib 25 mg, Placebo
Insmed Incorporated, Insmed Incorporated
Non-Cystic Fibrosis Bronchiectasis
10/24
10/24
Oryzon_COVID: ORYZON to Initiate ESCAPE: a Phase II Clinical Trial to Test Efficacy of Vafidemstat in Severely ill COVID-19 Patients

Not yet recruiting
2
300
Spain
vafidemstat (ORY-2001) - Oryzon
Oryzon
Seriously ill COVID-19
 
 
Insmed Incorporated_COVID: Brensocatib (Formerly INS1007) to be Studied in Patients with Severe COVID-19 in Investigator-Initiated Trial

Recruiting
2
300
UK
brensocatib (INS1007) - Insmed
Insmed, AstraZeneca
COVID19
 
 
2018-003903-21: A Study to Assess the pharmacokinetics and pharmacodynamics of INS1007 Administered Once Daily in Patients with Granulomatosis with Polyangiitis (GPA)

Not yet recruiting
2
16
Europe
INS1007, Film-coated tablet
Insmed Incorporated, Insmed Incorporated
Granulomatosis with Polyangiitis (GPA, Wegener’s granulomatosis, Diseases [C] - Immune System Diseases [C20]
 
 
CEDAR, NCT06685835: A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS)

Recruiting
2
204
Europe, Canada, US, RoW
Brensocatib, INS1007, Placebo
Insmed Incorporated
Hidradenitis Suppurativa
05/26
01/27
BiRCh, NCT06013241: A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

Active, not recruiting
2
288
Europe, Canada, US, RoW
Brensocatib, INS1007, Placebo, Mometasone furoate nasal spray (MFNS)
Insmed Incorporated
Chronic Rhinosinusitis Without Nasal Polyps
08/25
09/25
NCT05927597: A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of INS1007 in Healthy Japanese and Caucasian Participants

Completed
1
82
US
INS1007, AZD7986, Brensocatib, Placebo
Insmed Incorporated
Healthy Volunteers
08/19
08/19
NCT05673603: A Study of Brensocatib Following a Single Oral Administration in Participants With or Without Renal Impairment

Completed
1
28
US
Brensocatib, INS1007
Insmed Incorporated
Renal Impairment
02/23
02/23
NCT05517525: A Study to Evaluate the Pharmacokinetics (PK) and Safety of a Single Dose of Brensocatib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment

Completed
1
30
US
Brensocatib, INS1007
Insmed Incorporated
Hepatic Impairment
06/23
06/23
NCT05826574: A Study to Assess Pharmacokinetics (PK) of Brensocatib Alone and With Multiple Doses of Rifampin or Esomeprozole in Healthy Participants

Completed
1
32
US
Brensocatib, INS1007, Rifampin, Esomeprazole
Insmed Incorporated
Healthy Volunteers
07/23
07/23
NCT05965570: A Study to Investigate Effect of Clarithromycin, a Strong CYP3A4 Inhibitor, on Brensocatib Pharmacokinetics in Healthy Participants

Completed
1
22
US
Brensocatib, INS1007, Clarithromycin
Insmed Incorporated
Healthy Volunteers
09/23
09/23
NCT06178783: A Study of the Palatability and Acceptability of Different Brensocatib Oral Liquid Formulations in Healthy Participants

Completed
1
20
US
Brensocatib, INS1007, AZD7986
Insmed Incorporated
Healthy Volunteers
01/24
01/24
INS1007, NCT06344728: A Study to Assess the Relative Bioavailability of Brensocatib Pediatric Oral Solution to Oral Tablets in Healthy Participants

Completed
1
24
US
Brensocatib Oral Solution, INS1007, Brensocatib Oral Tablet
Insmed Incorporated
Healthy Participants
05/24
05/24
NCT05344508: An Expanded Access Study to Assess Brensocatib for Participants With Non-Cystic Fibrosis Bronchiectasis

Available
N/A
NA
Brensocatib
Insmed Incorporated
Non-Cystic Fibrosis Bronchiectasis
 
 
treprostinil palmitil inhalation (INS1009) / Insmed
2022-001950-45: A study to evaluate the effects of Treprostinil Palmitil Inhalation Powder in participants with Pulmonary Hypertension with Interstitial Lung Disease Estudio para evaluar los efectos de treprostinil palmitilo en polvo para inhalación en pacientes con hipertensión pulmonar asociada a enfermedad pulmonar intersticial

Ongoing
2/3
32
Europe
Treprostinil Palmitil Inhalation Powder, INS1009, Inhalation powder
Insmed Incorporated, Insmed Incorporated
Pulmonary Hypertension Associated with Interstitial Lung Disease Hipertensión pulmonar asociada a enfermedad pulmonar intersticial, Participants with high blood pressure in the arteries of the lungs Participantes con presión alta en las arterias pulmonares, Diseases [C] - Respiratory Tract Diseases [C08]
 
 
NCT05649722 / 2022-001950-45: An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Active, not recruiting
2/3
31
Europe, RoW
Treprostinil Palmitil Inhalation Powder, INS1009, Placebo
Insmed Incorporated, Insmed Incorporated
Pulmonary Hypertension, Interstitial Lung Disease
03/26
03/26
NCT05649748 / 2022-001951-18: An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH)

Active, not recruiting
2/3
91
Europe, Japan, US, RoW
Treprostinil Palmitil, INS1009, Placebo
Insmed Incorporated, Insmed Incorporated
Pulmonary Arterial Hypertension
12/26
12/26
2021-001528-16: A study to evaluate the effects of Treprostinil Palmitil Inhalation Powder in participants with Pulmonary Arterial Hypertension. Estudio para evaluar los efectos de treprostinil palmitilo en polvo para inhalación en pacientes con hipertensión arterial pulmonar

Not yet recruiting
2
99
Europe
Treprostinil Palmitil Inhalation Powder, INS1009, Inhalation powder
Insmed Incorporated, INSMED INCORPORATED, Insmed Incorporated
Participants with Pulmonary Arterial Hypertension Pacientes con hipertensión arterial pulmonar, Participants with high blood pressure in the arteries of the lungs Pacientes con tensión sanguínea alta in las arterias de los pulmones, Diseases [C] - Respiratory Tract Diseases [C08]
 
 
2021-003294-66: A study to evaluate the effects of Treprostinil Palmitil Inhalation Powder in participants with Pulmonary Hypertension with Interstitial Lung Disease Estudio para evaluar los efectos de treprostinil palmitilo en polvo para inhalación en pacientes con hipertensión pulmonar asociada a enfermedad pulmonar intersticial

Not yet recruiting
2
32
Europe
Treprostinil Palmitil Inhalation Powder, INS1009, Inhalation powder
Insmed Incorporated, INSMED INCORPORATED, Insmed Incorporated
Pulmonary Hypertension Associated with Interstitial Lung Disease Hipertensión pulmonar asociada a enfermedad pulmonar intersticial, Participants with high blood pressure in the arteries of the lungs Pacientes con presión alta en las arterias pulmonares, Diseases [C] - Respiratory Tract Diseases [C08]
 
 
NCT05176951 / 2021-003294-66: A Study to Evaluate the Safety and Tolerability of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease

Completed
2
39
Europe, RoW
Treprostinil Palmitil, INS1009, Placebo
Insmed Incorporated, Insmed Incorporated
Pulmonary Hypertension
03/24
03/24
INS1009-202, NCT05147805 / 2021-001528-16: A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension

Completed
2
102
Europe, Japan, US, RoW
Treprostinil Palmitil, INS1009, Placebo
Insmed Incorporated, Insmed Incorporated
Pulmonary Arterial Hypertension
03/25
03/25
NCT06091579: A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder (TPIP) in Healthy Participants

Completed
1
42
US
Treprostinil Palmitil Inhalation Powder, INS1009, Placebo
Insmed Incorporated
Healthy Volunteers
01/21
01/21
NCT06939647: An Expanded Access Study to Assess Treprostinil Palmitil Inhalation Powder (TPIP) for Participants With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Available
N/A
NA
Treprostinil Palmitil
Insmed Incorporated
Pulmonary Arterial Hypertension, Pulmonary Hypertension, Interstitial Lung Disease
 
 
Undisclosed translation medicine for rare disease / Insmed
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Arikayce (amikacin liposome inhalation suspension) / Insmed
ARISE, NCT04677543 / 2020-002545-42: Validation of Patient Reported Outcome Measures in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex

Completed
3
99
Europe, US, RoW
ALIS, Amikacin liposome inhalation suspension, ARIKAYCE®, Azithromycin, AZI, Ethambutol, ETH, ELC, Empty liposome control
Insmed Incorporated
Mycobacterium Infections, Nontuberculous
05/23
05/23
ENCORE, NCT04677569 / 2020-003079-16: Study to Evaluate ALIS (Amikacin Liposome Inhalation Suspension) in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex

Active, not recruiting
3
425
Europe, Canada, Japan, US, RoW
ALIS, Amikacin liposome inhalation suspension, ARIKAYCE®, Azithromycin, AZI, Zithromax, Ethambutol, ETH, Myambutol, ELC (matching placebo for ALIS), Empty liposome control
Insmed Incorporated
Mycobacterium Infections, Nontuberculous
11/25
01/26
2005-004389-17: SAFETY AND TOLERABILITY STUDY OF SLIT AMIKACIN 500 MG ONCE DAILY FOR 14 DAYS BY INHALATION IN CYSTIC FIBROSIS STUDY SUBJECTS CHRONICALLY INFECTED WITH PSEUDOMONAS AERUGINOSA

Ongoing
2
10
Europe
SLIT Amikacin, TR02,
Transave, Inc
Cystic Fibrosis with mild to moderate obstructive lung disease and chronic infection with Pseudomonas aeruginosa
 
 
AKAPI, NCT06585020: Amikacin Liposome Inhalation Suspension for Treatment of Mycobacterium Xenopi Pulmonary Infection

Not yet recruiting
2
190
Europe
Arikayce, standard treatment
Centre Hospitalier Universitaire, Amiens, University Hospital, Angers, Hospital Avicenne, University Hospital, Bordeaux, University Hospital, Brest, CH Compiègne, Créteil Hospital, Centre Hospitalier Universitaire Dijon, University Hospital, Grenoble, Centre Hospitalier le Mans, Hôpital de la Croix-Rousse, APHM - Nord, Hôpital Saint Joseph, CH Mulhouse, CH Orléans, Tenon Hospital, Paris, Hôpital Necker-Enfants Malades, CH PERPIGNAN, Poitiers University Hospital, CH Pontoise, CHU de Reims, Rennes University Hospital, CHU de Rouen - Accueil, Central Hospital Saint Quentin, IHU Strasbourg, University Hospital, Tours, CH Abbeville, CH Cannes
Mycobacterium; Xenopi, Lung Diseases
08/26
08/27
NCT06238856: Single Dose Escalation Study of TR02 (Sustained Lipid Inhalation Technology [SLIT™] Amikacin) in Participants With Cystic Fibrosis (CF) Having Chronic Infections of Pseudomonas Aeruginosa

Completed
1
18
NA
SLIT™ Amikacin, TR02, Placebo
Insmed Incorporated
Cystic Fibrosis
02/05
02/05
NCT05999942: A Study to Investigate Lung Deposition of Inhaled Amikacin-loaded Liposomes in Healthy Male Participants

Completed
1
6
NA
Liposomal Amikacin for Inhalation, Amikacin Liposome Inhalation Suspension (ALIS),, Arikayce™
Insmed Incorporated
Healthy Volunteers
06/04
06/04
brensocatib (INS1007) / Insmed
ASPEN, NCT04594369 / 2020-003688-25: A Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib in Participants With Non-Cystic Fibrosis Bronchiectasis

Jan 2024 - Dec 2024: Data from ASPEN trial for non-cystic fibrosis bronchiectasis
Hourglass Apr 2024 - Jun 2024 : Q2'24 - Topline data from ASPEN trial for NCFB
Completed
3
1767
Europe, Canada, Japan, US, RoW
Brensocatib 10 mg, INS1007, Brensocatib 25 mg, Placebo
Insmed Incorporated, Insmed Incorporated
Non-Cystic Fibrosis Bronchiectasis
10/24
10/24
Oryzon_COVID: ORYZON to Initiate ESCAPE: a Phase II Clinical Trial to Test Efficacy of Vafidemstat in Severely ill COVID-19 Patients

Not yet recruiting
2
300
Spain
vafidemstat (ORY-2001) - Oryzon
Oryzon
Seriously ill COVID-19
 
 
Insmed Incorporated_COVID: Brensocatib (Formerly INS1007) to be Studied in Patients with Severe COVID-19 in Investigator-Initiated Trial

Recruiting
2
300
UK
brensocatib (INS1007) - Insmed
Insmed, AstraZeneca
COVID19
 
 
2018-003903-21: A Study to Assess the pharmacokinetics and pharmacodynamics of INS1007 Administered Once Daily in Patients with Granulomatosis with Polyangiitis (GPA)

Not yet recruiting
2
16
Europe
INS1007, Film-coated tablet
Insmed Incorporated, Insmed Incorporated
Granulomatosis with Polyangiitis (GPA, Wegener’s granulomatosis, Diseases [C] - Immune System Diseases [C20]
 
 
CEDAR, NCT06685835: A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS)

Recruiting
2
204
Europe, Canada, US, RoW
Brensocatib, INS1007, Placebo
Insmed Incorporated
Hidradenitis Suppurativa
05/26
01/27
BiRCh, NCT06013241: A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

Active, not recruiting
2
288
Europe, Canada, US, RoW
Brensocatib, INS1007, Placebo, Mometasone furoate nasal spray (MFNS)
Insmed Incorporated
Chronic Rhinosinusitis Without Nasal Polyps
08/25
09/25
NCT05927597: A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of INS1007 in Healthy Japanese and Caucasian Participants

Completed
1
82
US
INS1007, AZD7986, Brensocatib, Placebo
Insmed Incorporated
Healthy Volunteers
08/19
08/19
NCT05673603: A Study of Brensocatib Following a Single Oral Administration in Participants With or Without Renal Impairment

Completed
1
28
US
Brensocatib, INS1007
Insmed Incorporated
Renal Impairment
02/23
02/23
NCT05517525: A Study to Evaluate the Pharmacokinetics (PK) and Safety of a Single Dose of Brensocatib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment

Completed
1
30
US
Brensocatib, INS1007
Insmed Incorporated
Hepatic Impairment
06/23
06/23
NCT05826574: A Study to Assess Pharmacokinetics (PK) of Brensocatib Alone and With Multiple Doses of Rifampin or Esomeprozole in Healthy Participants

Completed
1
32
US
Brensocatib, INS1007, Rifampin, Esomeprazole
Insmed Incorporated
Healthy Volunteers
07/23
07/23
NCT05965570: A Study to Investigate Effect of Clarithromycin, a Strong CYP3A4 Inhibitor, on Brensocatib Pharmacokinetics in Healthy Participants

Completed
1
22
US
Brensocatib, INS1007, Clarithromycin
Insmed Incorporated
Healthy Volunteers
09/23
09/23
NCT06178783: A Study of the Palatability and Acceptability of Different Brensocatib Oral Liquid Formulations in Healthy Participants

Completed
1
20
US
Brensocatib, INS1007, AZD7986
Insmed Incorporated
Healthy Volunteers
01/24
01/24
INS1007, NCT06344728: A Study to Assess the Relative Bioavailability of Brensocatib Pediatric Oral Solution to Oral Tablets in Healthy Participants

Completed
1
24
US
Brensocatib Oral Solution, INS1007, Brensocatib Oral Tablet
Insmed Incorporated
Healthy Participants
05/24
05/24
NCT05344508: An Expanded Access Study to Assess Brensocatib for Participants With Non-Cystic Fibrosis Bronchiectasis

Available
N/A
NA
Brensocatib
Insmed Incorporated
Non-Cystic Fibrosis Bronchiectasis
 
 
treprostinil palmitil inhalation (INS1009) / Insmed
2022-001950-45: A study to evaluate the effects of Treprostinil Palmitil Inhalation Powder in participants with Pulmonary Hypertension with Interstitial Lung Disease Estudio para evaluar los efectos de treprostinil palmitilo en polvo para inhalación en pacientes con hipertensión pulmonar asociada a enfermedad pulmonar intersticial

Ongoing
2/3
32
Europe
Treprostinil Palmitil Inhalation Powder, INS1009, Inhalation powder
Insmed Incorporated, Insmed Incorporated
Pulmonary Hypertension Associated with Interstitial Lung Disease Hipertensión pulmonar asociada a enfermedad pulmonar intersticial, Participants with high blood pressure in the arteries of the lungs Participantes con presión alta en las arterias pulmonares, Diseases [C] - Respiratory Tract Diseases [C08]
 
 
NCT05649722 / 2022-001950-45: An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Active, not recruiting
2/3
31
Europe, RoW
Treprostinil Palmitil Inhalation Powder, INS1009, Placebo
Insmed Incorporated, Insmed Incorporated
Pulmonary Hypertension, Interstitial Lung Disease
03/26
03/26
NCT05649748 / 2022-001951-18: An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH)

Active, not recruiting
2/3
91
Europe, Japan, US, RoW
Treprostinil Palmitil, INS1009, Placebo
Insmed Incorporated, Insmed Incorporated
Pulmonary Arterial Hypertension
12/26
12/26
2021-001528-16: A study to evaluate the effects of Treprostinil Palmitil Inhalation Powder in participants with Pulmonary Arterial Hypertension. Estudio para evaluar los efectos de treprostinil palmitilo en polvo para inhalación en pacientes con hipertensión arterial pulmonar

Not yet recruiting
2
99
Europe
Treprostinil Palmitil Inhalation Powder, INS1009, Inhalation powder
Insmed Incorporated, INSMED INCORPORATED, Insmed Incorporated
Participants with Pulmonary Arterial Hypertension Pacientes con hipertensión arterial pulmonar, Participants with high blood pressure in the arteries of the lungs Pacientes con tensión sanguínea alta in las arterias de los pulmones, Diseases [C] - Respiratory Tract Diseases [C08]
 
 
2021-003294-66: A study to evaluate the effects of Treprostinil Palmitil Inhalation Powder in participants with Pulmonary Hypertension with Interstitial Lung Disease Estudio para evaluar los efectos de treprostinil palmitilo en polvo para inhalación en pacientes con hipertensión pulmonar asociada a enfermedad pulmonar intersticial

Not yet recruiting
2
32
Europe
Treprostinil Palmitil Inhalation Powder, INS1009, Inhalation powder
Insmed Incorporated, INSMED INCORPORATED, Insmed Incorporated
Pulmonary Hypertension Associated with Interstitial Lung Disease Hipertensión pulmonar asociada a enfermedad pulmonar intersticial, Participants with high blood pressure in the arteries of the lungs Pacientes con presión alta en las arterias pulmonares, Diseases [C] - Respiratory Tract Diseases [C08]
 
 
NCT05176951 / 2021-003294-66: A Study to Evaluate the Safety and Tolerability of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease

Completed
2
39
Europe, RoW
Treprostinil Palmitil, INS1009, Placebo
Insmed Incorporated, Insmed Incorporated
Pulmonary Hypertension
03/24
03/24
INS1009-202, NCT05147805 / 2021-001528-16: A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension

Completed
2
102
Europe, Japan, US, RoW
Treprostinil Palmitil, INS1009, Placebo
Insmed Incorporated, Insmed Incorporated
Pulmonary Arterial Hypertension
03/25
03/25
NCT06091579: A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder (TPIP) in Healthy Participants

Completed
1
42
US
Treprostinil Palmitil Inhalation Powder, INS1009, Placebo
Insmed Incorporated
Healthy Volunteers
01/21
01/21
NCT06939647: An Expanded Access Study to Assess Treprostinil Palmitil Inhalation Powder (TPIP) for Participants With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Available
N/A
NA
Treprostinil Palmitil
Insmed Incorporated
Pulmonary Arterial Hypertension, Pulmonary Hypertension, Interstitial Lung Disease
 
 
Undisclosed translation medicine for rare disease / Insmed
No trials found

Download Options